Chemistry:ONX-0801
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C33H31N5O10 |
| Molar mass | 657.636 g·mol−1 |
| 3D model (JSmol) | |
| |
ONX-0801 (BGC 945) is an experimental drug that has been developed to target ovarian cancer.[1] It is a folate receptor alpha mediated thymidylate synthase inhibitor.[2][3]
ONX-0801 was originally developed by BTG and the Institute of Cancer Research in the UK, and subsequently licensed to Onyx Pharmaceuticals for clinical development. It is designed to selectively target tumour tissues of certain kinds of cancer.[4] It is poorly absorbed into most cells, but is actively transported by folate receptor alpha (FRα), which is usually only expressed at low levels in the apical membrane of some specialised tissues, but is expressed at much higher levels in some subtypes of ovarian cancer. This causes the drug to accumulate selectively in tumour tissues, while healthy tissues are only exposed to a much lower concentration.[5][6][7]
In 2017, it received press coverage following the successful completion of a Phase I clinical trial.[8][9][10]
References
- ↑ "Ovarian cancer drug delivers 'very promising' results in early trial". 3 June 2017. http://www.icr.ac.uk/news-archive/ovarian-cancer-drug-delivers-very-promising-results-in-early-trial.
- ↑ "A Phase I trial of ONX-0801" (in en-US). Health Research Authority. 19 July 2013. http://www.hra.nhs.uk/news/research-summaries/a-phase-i-trial-of-onx-0801/.
- ↑ "Antifolate inhibitors of thymidylate synthase as anticancer drugs". Mini Reviews in Medicinal Chemistry 10 (13): 1211–22. November 2010. doi:10.2174/13895575110091211. PMID 20854257.
- ↑ "BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors". Cancer Research 65 (24): 11721–8. December 2005. doi:10.1158/0008-5472.CAN-05-2034. PMID 16357184.
- ↑ Ng C, et al. Efficacy and tolerability of the thymidylate synthase (TS) inhibitor, BGC 945 is mediated through its selective uptake via the α-folate receptor (α-FR) in IGROV-1 human tumor xenografts. Cancer Res May 1, 2008 (68) (9 Supplement): 3289.
- ↑ "Potential for α-folate receptor-targeted treatment for ovarian cancer.". Emerging Therapeutic Targets in Ovarian Cancer. New York, NY.: Springer. 2011. pp. 245–258.
- ↑ "Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[gquinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells"]. Journal of Medicinal Chemistry 56 (13): 5446–55. July 2013. doi:10.1021/jm400490e. PMID 23710599.
- ↑ Warry, Richard (2017-06-03). "Drug shrinks ovarian tumours in early trial" (in en-GB). BBC News. https://www.bbc.co.uk/news/health-40097274.
- ↑ "Researchers hail biggest breakthrough in advanced ovarian cancer for a decade" (in en-GB). The Independent. 2017-06-02. https://www.independent.co.uk/news/health/ovarian-cancer-treatment-advanced-latest-tumours-breakthrough-a7769746.html.
- ↑ "An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.". Journal of Clinical Oncology 35 (suppl): abstr 2503. 2017. doi:10.1200/JCO.2017.35.15_suppl.2503. http://abstracts.asco.org/199/AbstView_199_182632.html.
 |  |
